Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
received:
16
10
2021
accepted:
09
09
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
6
10
2022
Statut:
epublish
Résumé
Lethal giant larvae homolog 2 (LLGL2) and solute carrier family 7 member 5 (SLC7A5) have been reported to be involved in resistance to endocrine therapy. This study aimed to assess the effects of LLGL2/SLC7A5 co-expression in predicting prognosis and response to tamoxifen therapy in ERα-positive breast cancer patients according to LLGL2/SLC7A5 mRNA and protein expression in long-term follow-up invasive breast cancer tissues. We identified that low LLGL2/SLC7A5 mRNA co-expression (LLGL2
Identifiants
pubmed: 36192404
doi: 10.1038/s41598-022-20225-4
pii: 10.1038/s41598-022-20225-4
pmc: PMC9529905
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Cytoskeletal Proteins
0
Estrogen Receptor alpha
0
Large Neutral Amino Acid-Transporter 1
0
RNA, Messenger
0
SLC7A5 protein, human
0
llgl2 protein, human
0
Tamoxifen
094ZI81Y45
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16515Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2007 Oct 20;25(30):4772-8
pubmed: 17876012
Int J Mol Sci. 2020 Feb 19;21(4):
pubmed: 32093034
Toxicol Pathol. 2012 Jul;40(5):715-21
pubmed: 22569583
Sci Rep. 2020 Jan 28;10(1):1292
pubmed: 31992742
Sci Rep. 2019 Nov 20;9(1):16776
pubmed: 31748583
Clin Cancer Res. 2004 Sep 1;10(17):5670-6
pubmed: 15355892
J Biol Chem. 1998 Sep 11;273(37):23629-32
pubmed: 9726963
J Clin Oncol. 2012 Dec 20;30(36):4477-84
pubmed: 23045591
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Nature. 2019 May;569(7755):275-279
pubmed: 30996345
Breast Cancer Res Treat. 2013 Jul;140(2):219-32
pubmed: 23836010
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Oncogene. 2009 Aug;28 Suppl 1:S14-23
pubmed: 19680292
Int J Mol Sci. 2018 Mar 19;19(3):
pubmed: 29562706
EMBO J. 2013 Mar 6;32(5):617-28
pubmed: 23395906
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Breast Cancer Res. 2018 Mar 22;20(1):21
pubmed: 29566741
Breast Cancer Res Treat. 2021 May;187(1):81-93
pubmed: 33782811
Breast Cancer Res. 2011 Mar 01;13(2):R21
pubmed: 21362200
Breast Cancer Res Treat. 2019 May;175(1):27-38
pubmed: 30671766
Int J Cancer. 2006 Aug 1;119(3):484-92
pubmed: 16496379
J Clin Oncol. 2001 Jan 15;19(2):354-63
pubmed: 11208826
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
Br J Cancer. 2020 Jan;122(1):94-101
pubmed: 31819174
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Am J Cancer Res. 2015 Mar 15;5(4):1281-94
pubmed: 26101697
Hum Pathol. 2005 Mar;36(3):250-61
pubmed: 15791569